Two Sigma Advisers’s Agilon Health AGL Stock Holding History

Two Sigma Advisers’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,568	Closed	-$767K	–	59
2025 Q4	$767K	Buy	+44,568	New	+$864K	﹤0.01%	1615
2025 Q1	–	Sell	-19,232	Closed	-$914K	–	2369
2024 Q4	$914K	Buy	19,232 +18,804	+4,393%	+$1.14M	﹤0.01%	1505
2024 Q3	$42.1K	Buy	+428	New	+$55.3K	﹤0.01%	2225

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NPCM

North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Two Sigma Advisers's AGL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Agilon Health (AGL) in Q1 2026, closing a stake of 44,568 shares — an estimated $767K sold.

Two Sigma Advisers first reported a position in AGL in Q3 2024 and held it in 3 quarters. The position peaked at $914K in Q4 2024. 97 funds tracked by Wall St. Rank hold AGL as of Q1 2026.

Two Sigma Advisers reported no remaining Agilon Health position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 44,568 Agilon Health shares in Q1 2026, an estimated $767K.
Two Sigma Advisers first reported a position in Agilon Health in Q3 2024 and held it in 3 quarters.
Two Sigma Advisers's Agilon Health position peaked at $914K in Q4 2024.
97 funds tracked by Wall St. Rank held Agilon Health as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.